Evidence map›Paper›PMID 27988423›Full record

ArticleTranslational oncology2017

MTSS1 is epigenetically regulated in glioma cells and inhibits glioma cell motility.

Daniel Luxen, Gerrit H Gielen, Anke Waha, Lukas Isselstein, Tim Müller, Philipp Koch, Jennifer Hammes, Albert Becker, Matthias Simon, Peter Wurst and 4 more

Open access · goldAbstract read
In one paragraph

Article in Translational oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. MTSS1: beyond the integration of actin and membrane dynamics.Cellular and molecular life sciences : CMLS · 2024
    Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Daniel LuxenDepartment of Neuropathology, University of Bonn, Germany.
Gerrit H GielenDepartment of Neuropathology, University of Bonn, Germany.
Anke WahaDepartment of Neuropathology, University of Bonn, Germany.
Lukas IsselsteinDepartment of Neuropathology, University of Bonn, Germany.
Tim MüllerDepartment of Neuropathology, University of Bonn, Germany.
Philipp KochInstitute of Reconstructive Neurobiology, LIFE & BRAIN, University of Bonn, Germany.
Jennifer HammesDepartment of Neuropathology, University of Bonn, Germany.
Albert BeckerDepartment of Neuropathology, University of Bonn, Germany.
Matthias SimonInstitute of Neurosurgery, University of Bonn, Germany.
Peter WurstDepartment of Molecular Medicine and Experimental Immunology, (Core Facility Flow Cytometry) University of Bonn, Germany.
Elmar EndlDepartment of Molecular Medicine and Experimental Immunology, (Core Facility Flow Cytometry) University of Bonn, Germany.
Torsten PietschDepartment of Neuropathology, University of Bonn, Germany.
Marco GessiDepartment of Neuropathology, University of Bonn, Germany.
Andreas WahaDepartment of Neuropathology, University of Bonn, Germany. Electronic address: awaha@uni-bonn.de.
University of Bonn · DELife & Brain (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epigenetic silencing by DNA methylation in brain tumors has been reported for many genes, however, their function on pathogenesis needs to be evaluated. We investigated the MTSS1 gene, identified as hypermethylated by differential methylation hybridization (DMH). Fifty-nine glioma tissue samples and seven glioma cell lines were examined for hypermethylation of the MTSS1 promotor, MTSS1 expression levels and gene dosage. GBM cell lines were treated with demethylating agents and interrogated for functional consequences of MTSS1 expression after transient transfection. Hypermethylation was significantly associated with IDH1/2 mutation. Comparative SNP analysis indicates higher incidence of loss of heterozygosity of MTSS1 in anaplastic astrocytomas and secondary glioblastomas as well as hypermethylation of the remaining allele. Reversal of promoter hypermethylation results in an increased MTSS1 expression. Cell motility was significantly inhibited by MTSS1 overexpression without influencing cell growth or apoptosis. Immunofluorescence analysis of MTSS1 in human astrocytes indicates co-localization with actin filaments. MTSS1 is down-regulated by DNA methylation in glioblastoma cell lines and is part of the G-CIMP phenotype in primary glioma tissues. Our data on normal astrocytes suggest a function of MTSS1 at focal contact structures with an impact on migratory capacity but no influence on apoptosis or cellular proliferation.

Identifiers

PMID27988423
PMCPMC5167248
OpenAlexW2562383780

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.